- Dr Martens anticipates revenue, profit decline from US sales
- Sales projected to drop 11% to £900 million
- Profits expected to fall by a third to £125 million
Dr Marten anticipates a substantial revenue and profit decline due to decreased United States sales.
The London-listed company’s sales are projected to shrink to £900 million, marking an 11% decline from the previous year, a period when it celebrated its first $1 billion milestone.
According to city analysts, when the cult bootmaker declares its full-year results on Thursday, profits are expected to decrease by a third to £125m.
“Start your investing journey with a gift! Claim your free Webull shares.”
Dr. Martens has experienced a revenue decline, as evidenced by the double-digit declines in the United States in its April trading update.
The footwear brand’s share price has declined by 80% since its stock market debut three years ago.
